相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。c-Met inhibition enhances chemosensitivity of human ovarian cancer cells
Jing Wang et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway
E. Leung et al.
ONCOGENE (2017)
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
Ignace B. Vergote et al.
EUROPEAN JOURNAL OF CANCER (2017)
Tivantinib for the treatment of hepatocellular carcinoma
Jan Best et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Samuel J. Klempner et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Role of long non-coding RNAs in glucose metabolism in cancer
Chunmei Fan et al.
MOLECULAR CANCER (2017)
Circular RNAs in human cancer
Yumin Wang et al.
MOLECULAR CANCER (2017)
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
Agnieszka A. Rucki et al.
MOLECULAR CANCER THERAPEUTICS (2017)
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Ravi Salgia
MOLECULAR CANCER THERAPEUTICS (2017)
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Hanyin Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2017)
RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells
Binbin Yin et al.
ONCOLOGY REPORTS (2017)
The c-Met receptor: Implication for targeted therapies in colorectal cancer
Elmira Safaie Qamsari et al.
TUMOR BIOLOGY (2017)
The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells
Terumichi Shintani et al.
UROLOGY (2017)
Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell
Ying Liang et al.
ONCOLOGY LETTERS (2017)
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
Sean Caenepeel et al.
Oncotarget (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Aryan Stanley et al.
SCIENTIFIC REPORTS (2017)
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target
S. Pilotto et al.
CANCER TREATMENT REVIEWS (2017)
Complexity of the Wnt/β-catenin pathway: Searching for an activation model
Giovane G. Tortelote et al.
CELLULAR SIGNALLING (2017)
Tumour acidosis: from the passenger to the driver's seat
Cyril Corbet et al.
NATURE REVIEWS CANCER (2017)
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
Stephen K. Chia et al.
BREAST CANCER RESEARCH (2017)
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
Francesco Facchinetti et al.
CANCER TREATMENT REVIEWS (2017)
A mini-review of c-Met as a potential therapeutic target in melanoma
Doa'a G. F. Al-U'datt et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications
Ralf Hass et al.
CELL COMMUNICATION AND SIGNALING (2017)
Understanding c-MET signalling in squamous cell carcinoma of the head & neck
P. Szturz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
Meghan Shea et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma
Yoshinori Imura et al.
CANCER SCIENCE (2016)
Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
Wen-Ting Liu et al.
CELL CYCLE (2016)
Cabozantinib for the treatment of renal cell carcinoma
Bernard Escudier et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer
Cunen Wu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells
Linyu Zhu et al.
JOURNAL OF CELL SCIENCE (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E. Hughes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
Samarpita Barat et al.
MOLECULAR CARCINOGENESIS (2016)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender et al.
NATURE MEDICINE (2016)
Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
Boram Kim et al.
PHYTOTHERAPY RESEARCH (2016)
Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells
Jian-Ching Wu et al.
PROSTATE (2016)
Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
Rachel Barrow-McGee et al.
NATURE COMMUNICATIONS (2016)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
Effects of Exercise on Tumor Physiology and Metabolism
Line Pedersen et al.
CANCER JOURNAL (2015)
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
Takuji Okusaka et al.
CANCER SCIENCE (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
Qingfeng Xiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
Igor Puzanov et al.
INVESTIGATIONAL NEW DRUGS (2015)
c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Giuditta Viticchie et al.
BIOMEDICINES (2015)
Targeting the MET gene for the treatment of non-small-cell lung cancer
F. Gelsomino et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
Marisa Mariani et al.
ONCOTARGET (2014)
EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
Jerrica L. Breindel et al.
CANCER RESEARCH (2013)
The Wnt/β-catenin pathway in ovarian cancer: A review
Rebecca C. Arend et al.
GYNECOLOGIC ONCOLOGY (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells
Kang Ho Kim et al.
NEURO-ONCOLOGY (2013)
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A. Shah et al.
PLOS ONE (2013)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
Frauke Bentzien et al.
THYROID (2013)
Combined Wnt/β-Catenin, Met, and CXCL12/CXCR4 Signals Characterize Basal Breast Cancer and Predict Disease Outcome
Jane D. Holland et al.
CELL REPORTS (2013)
Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
S. Zhao et al.
ONCOGENESIS (2013)
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wei Wang et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the HGF/Met signaling pathway in cancer therapy
Fabiola Cecchi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
Sara Previdi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells
Kiran Kumar Velpula et al.
TRANSLATIONAL ONCOLOGY (2012)
Lung Cancer: New Biological Insights and Recent Therapeutic Advances
Suresh S. Ramalingam et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
Silvia Benvenuti et al.
CANCER RESEARCH (2011)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
c-Met Represents a Potential Therapeutic Target for Personalized Treatment in Hepatocellular Carcinoma
Hanning You et al.
HEPATOLOGY (2011)
Distinct Involvement of the Gab1 and Grb2 Adaptor Proteins in Signal Transduction by the Related Receptor Tyrosine Kinases RON and MET
Amitabha Chaudhuri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
Elisa Benedettini et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
Jocelyn Logan-Collins et al.
CANCER RESEARCH (2010)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
Targeting the HGF/Met signalling pathway in cancer
Fabiola Cecchi et al.
EUROPEAN JOURNAL OF CANCER (2010)
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
Sara Previdi et al.
EUROPEAN JOURNAL OF CANCER (2010)
Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines
Rebecca J. McClaine et al.
NEOPLASIA (2010)
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
S. Agarwal et al.
BRITISH JOURNAL OF CANCER (2009)
Role of Overexpression of CD151 and/or c-Met in Predicting Prognosis of Hepatocellular Carcinoma
Ai-Wu Ke et al.
HEPATOLOGY (2009)
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and wnt activity in colon cancer
Jurriaan B. Tuynman et al.
CANCER RESEARCH (2008)
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells
Kehy L. Mueller et al.
CANCER RESEARCH (2008)
AKT signaling in regulating angiogenesis
Bing-Hua Jiang et al.
CURRENT CANCER DRUG TARGETS (2008)
Smad4-dependent TGF-β signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells
Shujie Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Re: Prognostic value of MET, RON and, histoprognostic factors for urothelial carcinoma in the upper urinary tract
Jay D. Raman
JOURNAL OF UROLOGY (2008)
Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: A retrospective study
Zhi Li Wang et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
Pal Kaposi-Novak et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder
HL Cheng et al.
BRITISH JOURNAL OF CANCER (2005)
Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells
D Mottet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness
P Maggiora et al.
EXPERIMENTAL CELL RESEARCH (2003)
Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase
MH Wang et al.
CARCINOGENESIS (2003)
How to make tubes:: signaling by the Met receptor tyrosine kinase
M Rosário et al.
TRENDS IN CELL BIOLOGY (2003)
Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity
C Liebmann
CELLULAR SIGNALLING (2001)
Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis
BE Peace et al.
ONCOGENE (2001)
Cross-talk between the proto-oncogenes Met and Ron
A Follenzi et al.
ONCOGENE (2000)
分享论文
